Author Correction: Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy (Nature Communications, (2016), 7, 1, (11432), 10.1038/ncomms11432);Suppressor of IKKI> is an essential negative regulator of pathological cardiac hypertrophy

Nature Communications

Volumn 7, Issue , 2016, Pages

  Deng, Ke Qiong ^a,b,c   Wang, Aibing ^d   Ji, Yan Xiao ^a,b,c   Zhang, Xiao Jing ^a,b,c   Fang, Jing ^e   Zhang, Yan ^a,b,c   Zhang, Peng ^a,b,c   Jiang, Xi ^a,b,c   Gao, Lu ^e   Zhu, Xue Yong ^a,b,c   Zhao, Yichao ^f   Gao, Lingchen ^f   Yang, Qinglin ^g   Zhu, Xue Hai ^e   Wei, Xiang ^e   Pu, Jun ^f   Li, Hongliang ^a,b,c  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c WUHAN UNIVERSITY   (China)

^d HUNAN AGRICULTURAL UNIVERSITY   (China)

^e HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^f SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; I KAPPA B KINASE EPSILON; PROTEIN KINASE B; SUPPRESSOR OF I KAPPA B KINASE EPSILON; TANK BINDING KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UNCLASSIFIED DRUG; PROTEIN BINDING; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; SIKE PROTEIN, HUMAN; SIKE PROTEIN, MOUSE; TBK1 PROTEIN, MOUSE;

ENZYME ACTIVITY; INHIBITOR; MAMMAL; MOLECULAR ANALYSIS; MORBIDITY; MORTALITY; PATHOLOGY; PROTEIN; RODENT;

ARTICLE; CONGESTIVE CARDIOMYOPATHY; DOWN REGULATION; HEART FAILURE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE CELL; CARDIOMEGALY; DISEASE MODEL; FEMALE; GENETICS; KNOCKOUT MOUSE; MACACA FASCICULARIS; MALE; METABOLISM; MOUSE; PATHOLOGY; RAT; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALIA; MUS; PRIMATES; RATTUS; RODENTIA;

ANIMALS; CARDIOMEGALY; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MYOCYTES, CARDIAC; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; RATS; SIGNAL TRANSDUCTION;

EID: 84973397864     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-023-38331-w     Document Type: Erratum

References (39)

1. Heineke, J. & Molkentin, J. D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell Biol. 7, 589-600 (2006).
2. Bui, A. L., Horwich, T. B. & Fonarow, G. C. Epidemiology and risk profile of heart failure. Nat. Rev. Cardiol. 8, 30-41 (2011).
3. Planavila, A. et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat. Commun. 4, 2019 (2013).
4. Levy, D. et al. Long-Term trends in the incidence of and survival with heart failure. N. Engl. J. Med. 347, 1397-1402 (2002).
5. Ucar, A. et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat. Commun. 3, 1078 (2012).
6. Wang, J. et al. Tumor suppressor gene ING3 induces cardiomyocyte hypertrophy via inhibition of AMPK and activation of p38 MAPK signaling. Arch. Biochem. Biophys. 562, 22-30 (2014).
7. Bisserier, M. et al. Carabin protects against cardiac hypertrophy by blocking calcineurin, Ras, and Ca2?/calmodulin-dependent protein kinase II signaling. Circulation 131, 390-400 discussion 400 (2015).
8. Cotecchia, S., Del Vescovo, C. D., Colella, M., Caso, S. & Diviani, D. The alpha1-Adrenergic receptors in cardiac hypertrophy: Signaling mechanisms and functional implications. Cell. Signal. 27, 1984-1993 (2015).
9. van Berlo, J. H., Maillet, M. & Molkentin, J. D. Signaling effectors underlying pathologic growth and remodeling of the heart. J. Clin. Invest. 123, 37-45 (2013).
10. Jiang, D. S. et al. IRF8 suppresses pathological cardiac remodelling by inhibiting calcineurin signalling. Nat. Commun. 5, 3303 (2014).
11. Muthuramu, I. et al. Selective homocysteine-lowering gene transfer attenuates pressure overload-induced cardiomyopathy via reduced oxidative stress. J. Mol. Med. 93, 609-618 (2015).
12. Bajgelman, M. C. et al. Preservation of cardiac function in left ventricle cardiac hypertrophy using an AAV vector which provides VEGF-A expression in response to p53. Virology 476, 106-114 (2015).
13. Huang, J. et al. SIKE is an IKK epsilon/TBK1-Associated suppressor of TLR3-And virus-Triggered IRF-3 activation pathways. EMBO J. 24, 4018-4028 (2005).
14. Rose, B. A., Force, T. & Wang, Y. Mitogen-Activated protein kinase signaling in the heart: Angels versus demons in a heart-breaking tale. Physiol. Rev. 90, 1507-1546 (2010).
15. Kramann, N., Hasenfuss, G. & Seidler, T. B-RAF and its novel negative regulator reticulocalbin 1 (RCN1) modulates cardiomyocyte hypertrophy. Cardiovasc. Res. 102, 88-96 (2014).
16. Pillai, V. B., Sundaresan, N. R. & Gupta, M. P. Regulation of Akt signaling by sirtuins: its implication in cardiac hypertrophy and aging. Circ. Res. 114, 368-378 (2014).
17. Antos, C. L. et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc. Natl Acad. Sci. USA 99, 907-912 (2002).
18. Marion, J. D. et al. Mechanism of endogenous regulation of the type I interferon response by suppressor of IkappaB kinase epsilon (SIKE), a novel substrate of TANK-binding kinase 1 (TBK1).
19. J. Biol. Chem. 288, 18612-18623 (2013).
20. Jiang, X. et al. Tumor necrosis factor receptor-Associated factor 3 is a positive regulator of pathological cardiac hypertrophy. Hypertension 66, 356-367 (2015).
21. Shao, Y. et al. CRISPR/Cas-mediated genome editing in the rat via direct injection of one-cell embryos. Nat. Protoc. 9, 2493-2512 (2014).
22. Komuro, A., Bamming, D. & Horvath, C. M. Negative regulation of cytoplasmic RNA-mediated antiviral signaling. Cytokine 43, 350-358 (2008).
23. Piao, W. et al. Endotoxin tolerance dysregulates MyD88-And Toll/IL-1R domain-containing adapter inducing IFN-beta-dependent pathways and increases expression of negative regulators of TLR signaling. J. Leukoc. Biol. 86, 863-875 (2009).
24. Ito, M. et al. Peripheral B cells may serve as a reservoir for persistent hepatitis C virus infection. J. Innate Immun. 2, 607-617 (2010).
25. Zhao, W. Negative regulation of TBK1-mediated antiviral immunity. FEBS Lett. 587, 542-548 (2013).
26. Li, Y. et al. ISG56 is a negative-feedback regulator of virus-Triggered signaling and cellular antiviral response. Proc. Natl Acad. Sci. USA 106, 7945-7950 (2009).
27. Leotoing, L. et al. A20-binding inhibitor of nuclear factor-kappaB (NFkappaB)-2 (ABIN-2) is an activator of inhibitor of NF-kappaB (IkappaB) kinase alpha (IKKalpha)-mediated NF-kappaB transcriptional activity. J. Biol. Chem. 286, 32277-32288 (2011).
28. Kim, S. S. et al. DOK3 is required for IFN-beta production by enabling TRAF3/TBK1 complex formation and IRF3 activation. J. Immunol. 193, 840-848 (2014).
29. Ou, Y. H. et al. TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol. Cell 41, 458-470 (2011).
30. Yu, J. et al. Regulation of T-cell activation and migration by the kinase TBK1 during neuroinflammation. Nat. Commun. 6, 6074 (2015).
31. Lopez-Olaneta, M. M. et al. Induction of the calcineurin variant CnAbeta1 after myocardial infarction reduces post-infarction ventricular remodelling by promoting infarct vascularization. Cardiovasc. Res. 102, 396-406 (2014).
32. Jiang, D. S. et al. Interferon regulatory factor 9 protects against cardiac hypertrophy by targeting myocardin. Hypertension 63, 119-127 (2014).
33. Zhang, F. et al. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nature Biotechnol. 29, 149-153 (2011).
34. Jiang, D. S. et al. Interferon regulatory factor 7 functions as a novel negative regulator of pathological cardiac hypertrophy. Hypertension 63, 713-722 (2014).
35. Jiang, D. S. et al. Role of interferon regulatory factor 4 in the regulation of pathological cardiac hypertrophy. Hypertension 61, 1193-1202 (2013).
36. Jiang, D. S. et al. Interferon regulatory factor 1 is required for cardiac remodeling in response to pressure overload. Hypertension 64, 77-86 (2014).
37. Zhu, X. et al. Exacerbating pressure overload-induced cardiac hypertrophy: novel role of adaptor molecule Src homology 2-B3. Hypertension 66, 571-581 (2015).
38. Oka, T. et al. Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability. Circ. Res. 98, 837-845 (2006).
39. Bian, Z. Y. et al. Disruption of mindin exacerbates cardiac hypertrophy and fibrosis. J. Mol. Med. 90, 895-910 (2012).